Improving the MVA vaccine potential by deleting the viral gene coding for the IL-18 binding protein.

Improving the MVA vaccine potential by deleting the viral gene coding for the IL-18 binding protein.

BACKGROUND: Modified Vaccinia Ankara (MVA) is an attenuated strain of Vaccinia virus (VACV) currently employed in many clinical trials against HIV/AIDS and other diseases. MVA still retains genes involved in host immune response evasion, enabling its optimization by removing some of them. The aim of...

Full description

Bibliographic Details
Main Authors:	Juliana Falivene, María Paula Del Médico Zajac, María Fernanda Pascutti, Ana María Rodríguez, Cynthia Maeto, Beatriz Perdiguero, Carmen E Gómez, Mariano Esteban, Gabriela Calamante, María Magdalena Gherardi
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2012-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC3285208?pdf=render

Similar Items

Deletion of A44L, A46R and C12L Vaccinia Virus Genes from the MVA Genome Improved the Vector Immunogenicity by Modifying the Innate Immune Response Generating Enhanced and Optimized Specific T-Cell Responses
by: María Pía Holgado, et al.
Published: (2016-05-01)

IL-12 and GM-CSF in DNA/MVA immunizations against HIV-1 CRF12_BF Nef induced T-cell responses with an enhanced magnitude, breadth and quality.
by: Ana María Rodríguez, et al.
Published: (2012-01-01)

Novel mucosal DNA-MVA HIV vaccination in which DNA-IL-12 plus cholera toxin B subunit (CTB) cooperates to enhance cellular systemic and mucosal genital tract immunity.
by: Cynthia Maeto, et al.
Published: (2014-01-01)

IL-12 plus CTB in intranasal DNA-MVA schemes improved magnitude and quality of both systemic and mucosal HIV cellular immune responses
by: Rodriguez AM, et al.
Published: (2012-09-01)

T-cell immune responses against Env from CRF12_BF and subtype B HIV-1 show high clade-specificity that can be overridden by multiclade immunizations.
by: Daniela C Mónaco, et al.
Published: (2011-01-01)

IL-12 DNA Displays Efficient Adjuvant Effects Improving Immunogenicity of Ag85A in DNA Prime/MVA Boost Immunizations
by: María Paula Morelli, et al.
Published: (2020-09-01)

Deletion of Vaccinia Virus A40R Gene Improves the Immunogenicity of the HIV-1 Vaccine Candidate MVA-B
by: Patricia Pérez, et al.
Published: (2020-02-01)

Immune Modulation of NYVAC-Based HIV Vaccines by Combined Deletion of Viral Genes that Act on Several Signalling Pathways
by: Carmen Elena Gómez, et al.
Published: (2017-12-01)

Diseño y construcción de vectores de transferencia para la obtención de virus vaccinia Ankara modificado (MVA) recombinantes Design and construction of transfer vectors in order to obtain recombinant modified vaccinia virus Ankara (MVA)
by: M. F. Ferrer, et al.
Published: (2007-09-01)

Induction of Broad and Polyfunctional HIV-1-Specific T Cell Responses by the Multiepitopic Protein TMEP-B Vectored by MVA Virus
by: Beatriz Perdiguero, et al.
Published: (2019-06-01)

A Novel MVA-Based HIV Vaccine Candidate (MVA-gp145-GPN) Co-Expressing Clade C Membrane-Bound Trimeric gp145 Env and Gag-Induced Virus-Like Particles (VLPs) Triggered Broad and Multifunctional HIV-1-Specific T Cell and Antibody Responses
by: Beatriz Perdiguero, et al.
Published: (2019-02-01)

Immunogenic profiling in mice of a HIV/AIDS vaccine candidate (MVA-B) expressing four HIV-1 antigens and potentiation by specific gene deletions.
by: Juan García-Arriaza, et al.
Published: (2010-01-01)

An MVA-based vector expressing cell-free ISG15 increases IFN-I production and improves HIV-1-specific CD8 T cell immune responses
by: Michela Falqui, et al.
Published: (2023-05-01)

Potent HIV-1-Specific CD8 T Cell Responses Induced in Mice after Priming with a Multiepitopic DNA-TMEP and Boosting with the HIV Vaccine MVA-B
by: Beatriz Perdiguero, et al.
Published: (2018-08-01)

Improving Adaptive and Memory Immune Responses of an HIV/AIDS Vaccine Candidate MVA-B by Deletion of Vaccinia Virus Genes (C6L and K7R) Blocking Interferon Signaling Pathways.
by: Juan García-Arriaza, et al.
Published: (2013-01-01)

Enhancement of the HIV-1-Specific Immune Response Induced by an mRNA Vaccine through Boosting with a Poxvirus MVA Vector Expressing the Same Antigen
by: Carmen Elena Gómez, et al.
Published: (2021-08-01)

Optimized Hepatitis C Virus (HCV) E2 Glycoproteins and their Immunogenicity in Combination with MVA-HCV
by: María Q. Marín, et al.
Published: (2020-08-01)

Impact of viral infections on hematopoiesis: From beneficial to detrimental effects on bone marrow output.
by: Maria Fernanda Pascutti, et al.
Published: (2016-09-01)

Alphavirus replicon DNA expressing HIV antigens is an excellent prime for boosting with recombinant modified vaccinia Ankara (MVA) or with HIV gp140 protein antigen.
by: Maria L Knudsen, et al.
Published: (2015-01-01)

Interleukin-18, Functional IL-18 Receptor and IL-18 Binding Protein Expression in Active and Latent Tuberculosis
by: Sebastian Wawrocki, et al.
Published: (2020-06-01)

Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome.
by: Julie Delaloye, et al.
Published: (2009-06-01)

Inoculación de granadilla Passiflora ligularis L. con MVA
by: Sánchez de Prager Marina, et al.
Published: (1995-06-01)

MvaT binds to the PexsC promoter to repress the type III secretion system in Pseudomonas aeruginosa
by: Liwen Yin, et al.
Published: (2023-11-01)

Development of a Safe and Effective Vaccinia Virus Oncolytic Vector WR-Δ4 with a Set of Gene Deletions on Several Viral Pathways
by: Ernesto Mejías-Pérez, et al.
Published: (2018-03-01)

Transcriptomic response and immunological responses to chimpanzee adenovirus- and MVA viral-vectored vaccines for RSV in healthy adults
by: Green, C, et al.
Published: (2023)

Sequestration of Late Antigens Within Viral Factories Impairs MVA Vector-Induced Protective Memory CTL Responses
by: Sha Tao, et al.
Published: (2019-12-01)

Modified Vaccinia Virus Ankara (MVA) as Production Platform for Vaccines against Influenza and Other Viral Respiratory Diseases
by: Arwen F. Altenburg, et al.
Published: (2014-07-01)

Immune Profiles Identification by Vaccinomics After MVA Immunization in Randomized Clinical Study
by: Jorge Sanchez, et al.
Published: (2020-11-01)

Virological and immunological outcome of treatment interruption in HIV-1-infected subjects vaccinated with MVA-B.
by: Miriam Rosás-Umbert, et al.
Published: (2017-01-01)

Antibodies Elicited in Response to a Single Cycle Glycoprotein D Deletion Viral Vaccine Candidate Bind C1q and Activate Complement Mediated Neutralization and Cytolysis
by: Maria Luisa Visciano, et al.
Published: (2021-06-01)

Early skewed distribution of total and HIV-specific CD8+ T-cell memory phenotypes during primary HIV infection is related to reduced antiviral activity and faster disease progression.
by: Yanina Ghiglione, et al.
Published: (2014-01-01)

Callimaco, Ipponatte e la querelle di Bupalo. Un discorso sull’arte
by: Maria-Rosaria Falivene
Published: (2011-07-01)

DNA/MVA Vaccines for HIV/AIDS
by: Smita S. Iyer, et al.
Published: (2014-02-01)

Removal of the C6 Vaccinia Virus Interferon-β Inhibitor in the Hepatitis C Vaccine Candidate MVA-HCV Elicited in Mice High Immunogenicity in Spite of Reduced Host Gene Expression
by: María Q. Marín, et al.
Published: (2018-08-01)

Full efficacy and long-term immunogenicity induced by the SARS-CoV-2 vaccine candidate MVA-CoV2-S in mice
by: Adrián Lázaro-Frías, et al.
Published: (2022-02-01)

Deletion of short arm of chromosome 18, Del(18p) syndrome
by: Prashant Babaji, et al.
Published: (2014-01-01)

Systems analysis of MVA-C induced immune response reveals its significance as a vaccine candidate against HIV/AIDS of clade C.
by: Carmen Elena Gómez, et al.
Published: (2012-01-01)

Deletion of IL-18 Expression Ameliorates Spontaneous Kidney Failure in MRLlpr Mice.
by: Bastian Schirmer, et al.
Published: (2015-01-01)

Protection of IFNAR (-/-) mice against bluetongue virus serotype 8, by heterologous (DNA/rMVA) and homologous (rMVA/rMVA) vaccination, expressing outer-capsid protein VP2.
by: Tamara Kusay Jabbar, et al.
Published: (2013-01-01)

Editorial: Vaccination strategies against ruminant infectious diseases
by: Maria Paula Del Medico Zajac, et al.
Published: (2023-05-01)